Liquid vs. tissue-based NGS testing: How to choose and when to use

While tissue-based next generation sequencing (NGS) testing has been regarded as the gold-standard approach, there is an increasing push for the use of liquid-based NGS testing in the research setting, given its distinct advantages of convenience and its ability to potentially account for genomic heterogeneity. There are, however, distinct caveats that need to be considered before we can consider the findings of a liquid-based testing approach being as representative as a tissue-based one.

This webinar will help you:

• Taking lung cancer research as a prime example, evaluate the evidence of incorporating the use of NGS in the workup and management of clinical data, and how to choose between liquid- and tissue-based platforms.

Presented by:

Prof. Herbert Loong, MBBS(HK), PDipMDPath(HK), MRCP(UK), FHKCP, FHKAM(Medicine) Assistant Professor (Clinical) – Department of Clinical Oncology, The Chinese University of Hong Kong  Deputy Medical Director – Phase 1 Clinical Trials Centre, The Chinese University of Hong Kong